53 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
through a Special Protocol Assessment, Processa will be designing and conducting a Phase 3 trial to evaluate the ability of PCS499 to completely close
CORRESP
PCSA
Processa Pharmaceuticals Inc
9 Oct 18
Correspondence with SEC
12:00am
its fair value. Events that could result in an impairment, or trigger an interim impairment assessment, may include actions by regulatory authorities
10-K
8a6 fsvge2xnz
27 Mar 14
Annual report
12:00am
8-K
EX-99.1
riywf5s
12 Oct 17
Entry into a Material Definitive Agreement
12:00am
424B4
phtdaqhldxo cldau
5 Oct 20
Prospectus supplement with pricing info
4:16pm